Share on LinkedInShare on LinkedIn

ARTICLE · 03 APRIL 2019

Federal Circuit Patent Update - April 2, 2019

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

On appeal, three defendants appealed the judgment that U.S. Patent No. 7,994,364 is not invalid for obviousness or lack of utility.

United StatesIntellectual Property

Precedential Federal Circuit Opinions

1.                  FOREST LABORATORIES, LLC v. SIGMAPHARM LABORATORIES, LLC [OPINION - PRECEDENTIAL] (2017-2369, 2017-2370, 2017-2372, 2017-2373, 2017-2374, 2017-2375, 2017-2376, 2017-2389, 2017-2412, 2017-2436, 2017-2438, 2017-2440, 2017-2441, 03/14/2019) (PROST, DYKE, MOORE)  

Moore, J.  Vacating and remanding the district court's determinations regarding validity and infringement issues.  This appeal involves multiple Abbreviated New Drug Applications (ANDAs) filed with the Food and Drug Administration by companies seeking to market generic versions of Saphris, a drug product administered sublingually (i.e., dissolved under the tongue).  Regarding the validity issue, the Court remanded for the district court to make an express finding regarding one of the defendants' proposed motivations to combine prior art references that allegedly rendered the claims invalid as obvious.  The Court also affirmed the district

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from